Edition:
India

Lipocine Inc (LPCN.OQ)

LPCN.OQ on NASDAQ Stock Exchange Capital Market

1.86USD
18 Apr 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.86
Open
$1.94
Day's High
$1.94
Day's Low
$1.83
Volume
46,908
Avg. Vol
112,698
52-wk High
$2.64
52-wk Low
$1.03

Latest Key Developments (Source: Significant Developments)

Clarus Therapeutics Refutes Patent Infringement Complaint Brought By Lipocine
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Clarus Therapeutics::CLARUS THERAPEUTICS REFUTES PATENT INFRINGEMENT COMPLAINT BROUGHT BY LIPOCINE.  Full Article

Lipocine Seeks Injunction Against Marketing Of Clarus Therapeutics’Jatenzo
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Lipocine Inc ::LIPOCINE SEEKS INJUNCTION AGAINST THE MARKETING OF CLARUS THERAPEUTICS’ JATENZO® FOR TESTOSTERONE REPLACEMENT THERAPY.LIPOCINE-HAS FILED SUIT AGAINST CLARUS THERAPEUTICS IN U.S. DISTRICT COURT ALLEGING THAT CLARUS’S JATENZO PRODUCT INFRINGES 6 OF CO’S U.S. PATENTS.  Full Article

Lipocine Announces Financial And Operational Results For Year Ended Dec 31, 2018
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Lipocine Inc ::LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2018.LIPOCINE-AS OF DEC 31, 2018, CO HAD UNRESTRICTED CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AGGREGATING $15.3 MILLION, VERSUS $21.4 MILLION AT DEC 31, 2017.  Full Article

Lipocine Reports Q3 Loss Per Share Of $0.12
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Lipocine Inc ::LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018.Q3 LOSS PER SHARE $0.12.Q3 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, COMPANY HAD UNRESTRICTED CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $16.9 MILLION.  Full Article

Lipocine Announces Q1 Loss Per Share $0.13
Monday, 7 May 2018 

May 7 (Reuters) - Lipocine Inc ::LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2018.Q1 LOSS PER SHARE $0.13.Q1 EARNINGS PER SHARE VIEW $-0.21 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, COMPANY HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $27.8 MILLION.  Full Article

Lipocine Says ‍As Of December 31, 2017 Co Had Cash, Cash Equivalents And Marketable Securities Of $21.5 Mln​
Monday, 12 Mar 2018 

March 12 (Reuters) - Lipocine Inc ::LIPOCINE ANNOUNCES FINANCIAL AND OPERATIONAL RESULTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017.LIPOCINE INC - ‍AS OF DECEMBER 31, 2017, LIPOCINE HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $21.5 MILLION​.  Full Article

Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando
Thursday, 11 Jan 2018 

Jan 10 (Reuters) - Lipocine Inc ::LIPOCINE - FDA'S BRUDAC VOTED 6 IN FAVOR & 13 AGAINST BENEFIT/RISK PROFILE OF CO'S ORAL TESTOSTERONE PRODUCT CANDIDATE FOR TRT IN ADULT MALES, TLANDO.LIPOCINE INC SAYS ‍FDA DECISION ON TLANDO NDA IS ANTICIPATED BY ASSIGNED PDUFA GOAL DATE OF MAY 8, 2018 - SEC FILING ​.LIPOCINE INC - CONTINUE TO BELIEVE EFFICACY AND SAFETY RESULTS FROM CLINICAL STUDIES WITH TLANDO CONSISTENT WITH OTHER FDA APPROVED TRT PRODUCTS.  Full Article

Lipocine Says On Jan 5, Co, Unit, Silicon Valley Bank Entered Into Loan, Security Agreement
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Lipocine Inc ::LIPOCINE INC SAYS ON JAN 5, CO, UNIT, SILICON VALLEY BANK ("SVB") ENTERED INTO A LOAN AND SECURITY AGREEMENT -SEC FILING.LIPOCINE SAYS PURSUANT TO AGREEMENT SVB HAS AGREED TO LEND CO $10.0 MILLION; LOAN MATURES ON DEC 1, 2021.  Full Article

Lipocine says ‍FDA assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Lipocine Inc :U.S. FDA extends review for Tlando™; advisory committee meeting date of January 10, 2018 remains unchanged.Lipocine Inc - ‍FDA has assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​.  Full Article

Lipocine Inc Q3 loss per share $0.22
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Lipocine Inc :Lipocine announces financial and operational results for the third quarter and nine months ended September 30, 2017.Q3 loss per share $0.22.Q3 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article